Wall Street brokerages expect Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) to report ($1.13) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Entasis Therapeutics’ earnings. The lowest EPS estimate is ($1.15) and the highest is ($1.10). Entasis Therapeutics posted earnings of ($20.33) per share in the same quarter last year, which would indicate a positive year over year growth rate of 94.4%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 13th.
According to Zacks, analysts expect that Entasis Therapeutics will report full-year earnings of ($4.03) per share for the current year, with EPS estimates ranging from ($4.21) to ($3.84). For the next year, analysts anticipate that the business will report earnings of ($3.36) per share, with EPS estimates ranging from ($3.76) to ($2.96). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Entasis Therapeutics.
Entasis Therapeutics (NASDAQ:ETTX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.44).
A hedge fund recently raised its stake in Entasis Therapeutics stock. Janney Montgomery Scott LLC grew its stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 5.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,917 shares of the company’s stock after acquiring an additional 2,125 shares during the quarter. Janney Montgomery Scott LLC owned about 0.34% of Entasis Therapeutics worth $290,000 as of its most recent SEC filing. Institutional investors and hedge funds own 64.99% of the company’s stock.
Shares of ETTX traded down $0.12 during trading hours on Friday, reaching $5.68. 8,543 shares of the company traded hands, compared to its average volume of 28,841. The firm has a market cap of $73.68 million and a price-to-earnings ratio of -0.46. Entasis Therapeutics has a 12-month low of $3.97 and a 12-month high of $9.25. The company has a current ratio of 9.11, a quick ratio of 9.11 and a debt-to-equity ratio of 0.03. The stock’s fifty day moving average price is $6.66 and its 200 day moving average price is $6.53.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Further Reading: G-20
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.